Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
US6086914A · kind A · utility
10Cited by
2References
6Claims
0Family size
Inventors
Key dates
| Filing date | Mar 12, 1999 |
| Grant date | Jul 11, 2000 |
| Priority date | — |
| Expiry date | Mar 12, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/495
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
It is perceived that the newer antihistamines, which have been developed so as to be less sedating relative to the "first generation" antihistamines, possess diminished anticholinergic effects on rhinorrhea, compared to first-generation antihistamines. It is also perceived that no oral medicinal formulation is presently available for treatment of allergic rhinitis that provides both antihistaminic and anticholinergic actions and is unlikely to produce sedation. This invention provides such a formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.